source
- Moderna and Merck report late-stage success for personalized mRNA cancer vaccineModerna and Merck announced that their personalized cancer vaccine achieved its primary goals in a late-stage clinical trial, sparking enthusiasm across the biotech community. The experimental the…
- FDA approves Roivant's brepocitinib for rare autoimmune disease dermatomyositisOn Thursday the U.S. Food and Drug Administration gave its nod to a new therapy from Roivant Sciences and its subsidiary Priovant. The oral medication, brepocitinib, will be sold under the brand na…